Crewmembers: David Miller, MD; Esther Kim, MD; and Ehsan Rahimy, MD
The Mission: Retina specialists are continuing their mission to explore new technologies for treating wet AMD and DME, to seek out new means of reducing burden of care, and to boldly go where retina has not gone before!
Switching From Bevacizumab to Aflibercept 8 mg in a Patient With Neovascular AMD
Case Presented by Crewmember Ehsan Rahimy, MD
How might you approach an 84-year-old male who presents with acute-onset vision loss secondary to neovascular AMD in his better-seeing eye? Keep in mind, his contralateral eye has a 9-year history of anti-VEGF injections to treat the same condition. With 20/125 VA in that eye, making sure that his better-seeing eye remains functional is paramount to his health and quality of life.
What role did moving from bevacizumab (Avastin, Genentech) to a next-generation anti-VEGF play in his care? And how quickly did the eye respond?
Switching From Aflibercept 2 mg to Faricimab in a Patient With Newly Diagnosed Neovascular AMD and Worsening PED
Case Presented by Crewmember Esther Kim, MD
A 75-year-old white woman presents with reduced 20/125 pinhole test; 20/50 vision and a large pigment epithelium detachment (PED). The bad news: treatment with a legacy anti-VEGF agent isn’t addressing the PED, which is growing with each visit. A switch to a next-generation anti-VEGF agent adequately addresses the PED—but will it last?
Conversion to Neovascular AMD in a GA Patient With a 2-Year Treatment History
Case Presented by Crewmember David Miller, MD
What happens when an 80-year-old patient whose geographic atrophy (GA) has been treated for 2 years with complement inhibition presents with new-onset neovascular AMD? And what happens when Dr. Miller makes the jump to warp speed by beginning this patient on a next-generation treatment rather than beginning on a legacy agent?
Neovascular AMD (PCV Variant) Patient Switched to Two Different Next-Generation Therapies
Case Presented by Crewmember Ehsan Rahimy, MD
What do you do when a 65-year-old patient’s sudden vision loss secondary to neovascular AMD (which is itself linked with polypoidal choroidal vasculopathy or PCV) needs to be treated with three different anti-VEGF agents before resolution is observed?
